AMINOPLASMAL - E Ireland - English - HPRA (Health Products Regulatory Authority)

aminoplasmal - e

b. braun medical limited - isoleucine leucine lysine hydrochloride dl-methionine phenylalanine threonine tryptophan, l- valine arginine histidine alanine proline aspartic acid asparagine acetylcysteine glutamic acid ornithine hydrochloride serine tyrosine aminoacetic acid sodium acetate trihydrate potassium acetate magnesium acetate tetrahydrate sodium dihydrogen phosphate dihydrate sodium hydroxide malic acid - solution for infusion - 12.5 per cent

ISOLEUCINE - L Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

isoleucine - l

boehringer ingelheim animal health australia pty. ltd. - isoleucine - l - unknown - isoleucine - l amino acid-isoleucine-l active 0.0 - active constituent

TROPHAMINE- isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, cysteine hydrochlorid United States - English - NLM (National Library of Medicine)

trophamine- isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, cysteine hydrochlorid

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), cysteine hydrochlo - isoleucine 0.49 g in 100 ml - trophamine® is indicated for the nutritional support of infants (including those of low birth weight) and young pediatric patients requiring tpn via either central or peripheral infusion routes. parenteral nutrition with trophamine® is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see warnings , precautions, pediatric use , and dosage and administration . central venous infusion should b

AMINOSYN-PF- isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, a United States - English - NLM (National Library of Medicine)

aminosyn-pf- isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, a

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 534 mg in 100 ml - aminosyn-pf 7%, sulfite-free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring tpn via either central or peripheral infusion routes. parenteral nutrition with aminosyn-pf 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. see dosage and administration for additional information. central